Aurobindo Pharma Ltd
NSE:AUROPHARMA
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
989.8
1 568.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd
Revenue
Aurobindo Pharma Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aurobindo Pharma Ltd
NSE:AUROPHARMA
|
Revenue
₹297.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
12%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Revenue
₹289.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Revenue
₹265.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Revenue
₹503.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Revenue
₹112.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Revenue
₹103.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Aurobindo Pharma Ltd
Glance View
Aurobindo Pharma Ltd., a prominent player in the global generic pharmaceutical market, began its journey in 1986 with a vision to make high-quality medicines accessible to patients around the world. Over the years, the company has transformed into a diversified pharmaceutical powerhouse, producing a wide range of generic formulations, active pharmaceutical ingredients (APIs), and complex generics. Headquartered in Hyderabad, India, Aurobindo leverages robust research and development capabilities, along with an extensive manufacturing footprint that spans several countries, allowing it to cater to diverse markets, including the United States and Europe. With a commitment to quality and regulatory compliance, Aurobindo's products cover multiple therapeutic areas, including anti-retrovirals, antibiotics, cardiovascular, and central nervous system disorders, making it a well-regarded name in the industry. For investors, Aurobindo Pharma represents an attractive opportunity, given its consistent revenue growth and strategic focus on innovation. The company's investment in technology and its ability to navigate stringent regulatory landscapes enable it to maintain a competitive edge in the generics sector. Furthermore, Aurobindo's expanding portfolio of complex generics positions it to capture higher margins in the marketplace, while its strong presence in emerging markets ensures ongoing demand for its offerings. As the global healthcare landscape continues to evolve, Aurobindo Pharma's adaptability and commitment to sustainable growth make it a compelling choice for those looking to invest in a resilient and forward-thinking pharmaceutical enterprise.
See Also
What is Aurobindo Pharma Ltd's Revenue?
Revenue
297.2B
INR
Based on the financial report for Jun 30, 2024, Aurobindo Pharma Ltd's Revenue amounts to 297.2B INR.
What is Aurobindo Pharma Ltd's Revenue growth rate?
Revenue CAGR 10Y
12%
Over the last year, the Revenue growth was 17%. The average annual Revenue growth rates for Aurobindo Pharma Ltd have been 7% over the past three years , 7% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet
